Volume 11, Number 10—October 2005
Research
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1
Jon P. Furuno*
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡Table 2
Components of final logistic regression models*
| Characteristic | MRSA/VRE co-colonization, OR (95% CI) | VRE colonization, OR (95% CI) | MRSA colonization, OR (95% CI) |
|---|---|---|---|
| Age | 1.03 (1.01–1.05) | ||
| Male sex | 1.93 (1.14–3.3) | ||
| Admission to MICU | 4.38 (2.46–7.81) | 1.84 (1.38–2.46) | |
| Antimicrobial drugs during prior admission (<1 y) | 3.06 (1.85–5.07) | 3.38 (2.54–4.51) | 1.66 (1.20–2.30) |
| Diabetes mellitus | 1.39 (1.00–1.83) | 1.83 (1.30–2.58) | |
| Liver disease | 1.64 (1.04–2.58) | ||
| Renal disease | 2.28 (1.26–4.1) | ||
| Vancomycin | 1.54 (1.03–2.31) | ||
| Piperacillin-tazobactam | 1.77 (1.27–2.47) | ||
| Imipenem | 2.47 (1.40–4.36) | ||
| Fluoroquinolones | 2.01 (1.37–2.96) | ||
| HIV/AIDS | 2.74 (1.46–5.14) |
*Only variables significantly associated with the outcome are included in the final models. MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; OR, odds ratio; CI, confidence interval; MICU, medical intensive care unit.
1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.
2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
